Yes, you can transfer from Sequence to another GLP-1 provider — there's no clinical or legal barrier, just some sequencing to avoid a treatment gap or unnecessary dose reset.
Luma Health's flat semaglutide ($197/month) and tirzepatide ($297/month) include a medical evaluation to plan your transfer.
There's no rule preventing you from switching GLP-1 providers whenever you want — prescriptions aren't "locked" to a single platform. Here's how to make the transfer cleanly.
What Actually "Transfers" and What Doesn't
Your prescription itself doesn't transfer between platforms — a new provider writes a new prescription based on their own medical evaluation. What does transfer, informally, is your treatment history: your current medication, dose, how long you've been on it, and any side effects, which you share directly with your new provider so they can make an informed decision about your starting point rather than beginning from scratch unnecessarily.
Why Patients Commonly Transfer From Sequence
The most common reason is cost, since Sequence/WW Clinic's program fee (commonly $99-$249/month) is billed separately from medication, and the combined total for cash-pay patients often exceeds flat-rate compounded alternatives. Other reasons include wanting a simpler plan structure or not needing the platform's behavioral coaching and genetic-testing features.
How to Transfer Cleanly
Start your new provider's medical evaluation while you still have 2-3 weeks of medication remaining from Sequence. Provide your complete treatment history during intake. Once your new prescription is approved and shipping, cancel your Sequence membership, confirming your exact renewal date first to avoid an extra charge.
Generally no, if there's no significant gap in treatment and you share your current dose with your new provider — they can typically continue you at an appropriate dose rather than restarting titration. A dose reset becomes more likely if there's a meaningful gap (several weeks or more) between stopping with your old provider and starting with the new one, which is exactly why sequencing your transfer matters.
What About Lab Work?
If you've had recent labs done through Sequence, ask whether you can obtain a copy to share with your new provider — this can sometimes reduce or eliminate the need for a repeat lab panel, depending on how recent the results are and your new provider's specific requirements.
Making Your Transfer Smooth
- Your current medication, dose, and duration on treatment
- Any side effects experienced
- Recent lab results, if available, to share
- Starting your new evaluation before cancelling Sequence
- Timing cancellation just ahead of your next renewal date
- Confirming your new prescription ships before your old supply runs out
A simpler plan,
continuity built in
Compounded semaglutide at $197/month or tirzepatide at $297/month — medical evaluation, provider visits, and shipping all included.
Get Started → Or start your free health assessmentFrequently Asked Questions
Not directly — a new provider writes a new prescription based on their own evaluation. What transfers is your treatment history, which you share with them during intake.
Generally not, if there's no significant treatment gap and you share your current dose with your new provider, allowing them to continue at an appropriate level.
Start your new provider's evaluation while you still have 2-3 weeks of medication remaining, so your new prescription ships before your current supply runs out.
Possibly — ask Sequence for a copy of recent results and share them with your new provider, which may reduce or eliminate the need for repeat labs depending on recency and requirements.
After your new prescription is approved and shipping, timed just before your next Sequence renewal date to avoid an extra charge.
Not if you're staying on the same active ingredient (semaglutide or tirzepatide). The clinical mechanism is the same regardless of which licensed provider prescribes it.
References
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed 35441470
- U.S. Food and Drug Administration. Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide). FDA.gov. 2025. FDA Drug Approvals Database